Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (HK:8329)
:8329
Want to see HK:8329 full AI Analyst Report?
Top Page
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
(8329)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$0.13
▼(-21.88% Downside)
Action:ReiteratedDate:04/30/26
The score is mainly supported by balance-sheet conservatism and stronger 2025 cash generation, but is held back by deteriorating profitability (net loss and margin compression) and weak technicals with the stock trading below key moving averages and bearish momentum signals. Dividend yield is a modest positive, though the negative P/E reflects earnings pressure.
Positive Factors
Conservative Balance Sheet
Low and stable leverage around 0.10–0.13 gives the company durable financial flexibility. Over the next 2–6 months this conservatism supports funding of operations, R&D or working capital needs, cushions against shocks, and lowers refinancing risk versus peers with higher debt.
Negative Factors
Deteriorating Profitability
Significant margin compression to ~29% and a 2025 net loss reduce internal funding for R&D and commercialization. Persistently weaker margins erode competitive buffer, limit pricing power, and make returns sensitive to cost or pricing shocks across the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Low and stable leverage around 0.10–0.13 gives the company durable financial flexibility. Over the next 2–6 months this conservatism supports funding of operations, R&D or working capital needs, cushions against shocks, and lowers refinancing risk versus peers with higher debt.
Read all positive factors
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$213.11M
Dividend Yield3.51%
Average Volume (3M)330.65K
Price to Earnings (P/E)―
Beta (1Y)0.11
Revenue Growth-6.69%
EPS Growth-266.46%
CountryHK
Employees1,485
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding426,000,000
10 Day Avg. Volume371,000
30 Day Avg. Volume330,653
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.37
Price to Sales (P/S)0.25
P/FCF Ratio1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, researches, develops, produces, and sells medicines in the People's Republic of China. It is also involved in the purchase, sale, and distribution of medici...
How the Company Makes Money
null...
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
66
Positive
Cash Flow
71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 946.85M | 1.04B | 1.06B | 986.69M | 838.80M |
| Gross Profit | 277.58M | 328.04M | 439.24M | 444.14M | 374.10M |
| EBITDA | 37.16M | 62.87M | 69.89M | 125.24M | 73.97M |
| Net Income | -39.68M | 25.01M | 24.13M | 54.35M | 35.96M |
Balance Sheet | |||||
| Total Assets | 1.06B | 1.40B | 1.42B | 1.45B | 1.31B |
| Cash, Cash Equivalents and Short-Term Investments | 209.45M | 283.42M | 382.21M | 350.10M | 311.14M |
| Total Debt | 73.02M | 105.43M | 89.69M | 92.69M | 105.69M |
| Total Liabilities | 352.70M | 371.99M | 399.46M | 442.93M | 363.17M |
| Stockholders Equity | 647.73M | 933.18M | 908.17M | 884.04M | 829.70M |
Cash Flow | |||||
| Free Cash Flow | 124.95M | 2.20M | 38.32M | 41.51M | -85.00M |
| Operating Cash Flow | 139.59M | 24.41M | 53.69M | 61.22M | -69.92M |
| Investing Cash Flow | 83.26M | -114.62M | 60.90M | 10.76M | -181.57M |
| Financing Cash Flow | -306.92M | 1.43M | -32.48M | -9.02M | 66.75M |
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Technical Analysis
Negative
0.16
Price Trends
0.15
Negative
0.15
Negative
0.15
Negative
Market Momentum
>-0.01
Negative
34.15
Neutral
75.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8329, the sentiment is Negative. The current price of 0.16 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.15, and above the 200-day MA of 0.15, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 34.15 is Neutral, neither overbought nor oversold. The STOCH value of 75.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8329.
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | HK$213.11M | -1.02 | -6.17% | 3.51% | -6.69% | -266.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$808.75M | 11.90 | -3.39% | ― | -15.98% | 93.93% | |
48 Neutral | HK$607.36M | -13.53 | 9.48% | ― | -36.32% | 78.17% | |
47 Neutral | HK$167.53M | -40.12 | -11.77% | ― | 11.68% | -16.13% | |
46 Neutral | HK$401.18M | 43.63 | -1.17% | 7.50% | 59.60% | -351.02% | |
42 Neutral | HK$199.95M | -3.96 | -11.18% | ― | -2.12% | -13.99% |
* Healthcare Sector Average
HK:8329
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
0.13
-0.06
-33.16%
HK:0455
Tianda Pharmaceuticals Ltd.
0.09
-0.07
-42.59%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.36
0.01
2.86%
HK:1011
China NT Pharma Group Co., Ltd.
0.64
0.30
88.24%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.10
0.79
254.84%
HK:8622
Huakang Biomedical Holdings Company Limited
0.33
-0.09
-22.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.